Literature DB >> 539525

Breast cancer and histocompatibility antigens.

M L Subirá, C D Crisci, G Zornoza, M L Sanz, J Voltas, J L Hernández, A Oehling.   

Abstract

HLA antigens and haplotypes were studied in 50 women with infiltrating ductal carcinoma of the breast, from the Basque provinces and Navarra, and in a comtrol group consisted of 166 healthy persons from the same geographical area. A greater incidence of HLA-B7 and B26 was observed in the breast cancer group if compared with the frequency of occurrence of these antigens in the Spanish population. However, when compared with Navarra-Basque population, no significant differences were observed. The study of the haplotype frequencies in breast cancer showed a greater incidence of the A9, B27 and A10, B14 haplotypes than in the normal population. However, the significance of D values disappeared after making the necessary correction for the number of antigens tested. The major histocompatibility system has a variety of functions which have not yet been documented but that might predispose to disease. It is certainly probable that there will be multiple mechanisms underlying HLA and cancer associations, however so far none of the data available suggest the presence of an immune response gene linked with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 539525

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  2 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  HLA class II polymorphism: protective or risk factors to breast cancer in Tunisia?

Authors:  Amal Baccar Harrath; Besma Yacoubi Loueslati; Wafa Troudi; Slama Hmida; Syrine Sedkaoui; Amel Dridi; Afef Jridi; Farhat Ben Ayed; Khaled Ben Rhomdhane; Amel Ben Ammar Elgaaied
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.